Seres Therapeutics (MCRB) Competitors $0.46 -0.20 (-30.35%) Closing price 04:00 PM EasternExtended Trading$0.46 +0.00 (+0.22%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. CRMD, TYRA, PGEN, MAZE, ZVRA, RVNC, SIGA, DNA, SNDL, and AUTLShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include CorMedix (CRMD), Tyra Biosciences (TYRA), Precigen (PGEN), Maze Therapeutics (MAZE), Zevra Therapeutics (ZVRA), Revance Therapeutics (RVNC), SIGA Technologies (SIGA), Ginkgo Bioworks (DNA), SNDL (SNDL), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. CorMedix Tyra Biosciences Precigen Maze Therapeutics Zevra Therapeutics Revance Therapeutics SIGA Technologies Ginkgo Bioworks SNDL Autolus Therapeutics CorMedix (NASDAQ:CRMD) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Is CRMD or MCRB more profitable? Seres Therapeutics' return on equity of 0.00% beat CorMedix's return on equity.Company Net Margins Return on Equity Return on Assets CorMedixN/A -79.21% -64.68% Seres Therapeutics N/A N/A -55.08% Which has more volatility and risk, CRMD or MCRB? CorMedix has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.54, indicating that its stock price is 154% more volatile than the S&P 500. Do analysts rate CRMD or MCRB? CorMedix currently has a consensus target price of $14.50, suggesting a potential upside of 97.14%. Seres Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 736.82%. Given Seres Therapeutics' higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings and valuation, CRMD or MCRB? CorMedix has higher earnings, but lower revenue than Seres Therapeutics. CorMedix is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M11.03-$46.34M-$0.33-22.29Seres Therapeutics$126.33M0.66-$113.72M-$0.23-2.08 Does the media refer more to CRMD or MCRB? In the previous week, CorMedix had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 7 mentions for CorMedix and 4 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.51 beat CorMedix's score of 0.40 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in CRMD or MCRB? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 5.2% of CorMedix shares are held by insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer CRMD or MCRB? Seres Therapeutics received 498 more outperform votes than CorMedix when rated by MarketBeat users. However, 78.57% of users gave CorMedix an outperform vote while only 71.37% of users gave Seres Therapeutics an outperform vote. CompanyUnderperformOutperformCorMedixOutperform Votes3378.57% Underperform Votes921.43% Seres TherapeuticsOutperform Votes53171.37% Underperform Votes21328.63% SummarySeres Therapeutics beats CorMedix on 10 of the 18 factors compared between the two stocks. Remove Ads Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.34M$6.33B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-2.086.8121.8117.82Price / Sales0.66225.89379.3794.59Price / CashN/A65.6738.1534.64Price / Book-1.375.866.464.00Net Income-$113.72M$141.86M$3.20B$247.23M7 Day Performance-8.09%9.34%6.63%7.25%1 Month Performance-30.70%-12.34%-8.50%-6.24%1 Year Performance-22.64%-11.90%10.47%-0.17% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.0392 of 5 stars$0.46-30.3%$4.00+765.8%+1.3%$80.55M$126.33M-2.01330News CoverageGap DownCRMDCorMedix2.7641 of 5 stars$6.07+3.6%$15.14+149.5%+22.1%$395.66M$43.47M-7.4930Gap DownTYRATyra Biosciences2.0758 of 5 stars$7.38-4.7%$30.83+317.8%-43.4%$391.80MN/A-4.5820Positive NewsPGENPrecigen3.58 of 5 stars$1.33+7.3%$7.00+426.3%-1.4%$391.08M$3.93M-2.42190Gap DownMAZEMaze TherapeuticsN/A$8.92-1.7%$25.67+187.7%N/A$390.66M$167.50M0.00121Gap UpZVRAZevra Therapeutics2.2563 of 5 stars$7.05+0.1%$22.29+216.1%+45.4%$381.52M$23.61M-3.5820RVNCRevance Therapeutics2.0298 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500SIGASIGA Technologies1.8034 of 5 stars$5.33-1.1%N/A-30.2%$380.76M$138.72M4.4440Dividend AnnouncementPositive NewsGap DownDNAGinkgo Bioworks0.5882 of 5 stars$6.39+14.8%$4.58-28.4%N/A$371.07M$227.04M-0.49640SNDLSNDL2.9383 of 5 stars$1.33-2.9%$3.63+172.6%-33.5%$349.49M$920.45M-4.29580AUTLAutolus Therapeutics2.4667 of 5 stars$1.31-1.5%$9.32+611.5%-73.3%$348.58M$10.12M-1.08330Gap Up Remove Ads Related Companies and Tools Related Companies CRMD Competitors TYRA Competitors PGEN Competitors MAZE Competitors ZVRA Competitors RVNC Competitors SIGA Competitors DNA Competitors SNDL Competitors AUTL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MCRB Stock Free MCRB Stock Alerts